FDAnews Device Daily Bulletin
Medical Devices / Commercial Operations

SyntheticMR Introduces REMyDI

Nov. 29, 2016
A A

SyntheticMR introduced REMyDI, a device that automatically quantifies myelin volume in the brain.

The assessment of myelin allows clinicians to follow myelination in the developing brain and monitor myelin degeneration in patients with demyelinating and neurodegenerative disorders.

REMyDI is a feature of the SyMRI post-processing software from SyntheticMR. The REMyDI feature in SyMRI allows volume measurement of myelin from a single 5-6 minute quantitative MRI scan. The automatic post-processing is completed in 10 seconds.

The REMyDI feature is available in the SyMRI research edition package and will be available for clinical use in the SyMRI neuro package in 2017. — Cynthia Jessup

View today's stories